Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USDTTM unavailable because four recent quarterly reports are not available| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | - | - | - | - |
| Operating profit | $m | - | ||||||
| Net profit | $m | - | - | - | - | - | - | - |
| EPS reported | $ | - | ||||||
| Operating cashflow per share | $ | - | ||||||
| Capex per share | $ | - | ||||||
| FCF per share | $ | - | ||||||
| Free cash flow | $m | - | ||||||
| Net debt | $m | - | ||||||
| Book value equity | $m | - | ||||||
| Book value per share | $ | - | ||||||
| Number of shares | m | - | ||||||
| DPS (TTM paid) | $ | - |
Financial summary
Financials in USDTTM unavailable because four recent quarterly reports are not available| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | ||||||
| P/B LTM | x | - | ||||||
| P/S LTM | x | - | ||||||
| P/FCF LTM | x | - | ||||||
| EV/EBITDA LTM | x | - | ||||||
| EV/Sales LTM | x | - | ||||||
| Earnings Yield LTM | % | - | ||||||
| FCF Yield | % | - | ||||||
| Quality | ||||||||
| ROE | % | - | ||||||
| ROIC | % | - | ||||||
| Operating margin | % | - | ||||||
| Gross margin | % | - | ||||||
| FCF/Sales | % | - | ||||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | ||||||
| Sales Growth YoY | % | - | ||||||
| Net Income Growth YoY | % | - | ||||||
| FCF Growth | % | - | ||||||
| Operating Profit Growth | % | - | ||||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | - | ||||||
| Dividend Growth | % | - | ||||||
| Payout Ratio | % | - | ||||||
| FCF/Debt | x | - | ||||||
| Net Debt/EBITDA | x | - | ||||||
| EBIT/Net interest | x | - | ||||||
| Net debt/market cap | % | - | ||||||
| Net debt/Equity | x | - | ||||||
| Gross debt/equity | x | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Davion Healthcare Plc is an Irish public limited company that develops and commercializes non-invasive home tests for the early detection of health anomalies, including cancers. Its products use thermography: a liquid crystal film placed on the skin shows temperature differences as color shifts, and AI analysis of smartphone images interprets the result. It has four completed tests, BreastCheck, FootFlow (diabetic circulation), Testic and ThermaDerm, all non-diagnostic Class I devices. BreastCheck and FootFlow have been FDA-registered, and registered in the EU and UK, since November 2023. The company was incorporated in Cyprus in 2022 and re-domiciled to Ireland in 2024, keeping a wholly owned Cyprus subsidiary.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Davion Healthcare Plc is an Irish public limited company that develops and commercializes non-invasive home tests for the early detection of health anomalies, including cancers. Its products use thermography: a liquid crystal film placed on the skin shows temperature differences as color shifts, and AI analysis of smartphone images interprets the result. It has four completed tests, BreastCheck, FootFlow (diabetic circulation), Testic and ThermaDerm, all non-diagnostic Class I devices. BreastCheck and FootFlow have been FDA-registered, and registered in the EU and UK, since November 2023. The company was incorporated in Cyprus in 2022 and re-domiciled to Ireland in 2024, keeping a wholly owned Cyprus subsidiary.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free